Literature DB >> 8383206

The genetics of malignant hyperthermia.

S P Ball1, K J Johnson.   

Abstract

Malignant hyperthermia susceptibility remains the commonest cause of death owing to general anaesthesia. This is despite the availability of presymptomatic testing, admittedly by a highly invasive method, and a recognised treatment for implementation immediately a patient shows signs of developing a crisis. Recently the finding of linkage to markers from chromosome 19q13.1-13.2 and the identification of mutations in a candidate gene held out hope of genetic diagnosis being available. However, it is likely that only about 50% of families have a mutation of the skeletal muscle calcium release channel gene. With this degree of genetic heterogeneity, presymptomatic testing based on DNA markers can only be offered at present to a limited number of families where linkage to markers from 19q13.1-13.2 has been clearly shown.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8383206      PMCID: PMC1016259          DOI: 10.1136/jmg.30.2.89

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  45 in total

1.  HYPERTHERMIA DURING ANESTHESIA.

Authors:  L J SAIDMAN; E S HAVARD; E I EGER
Journal:  JAMA       Date:  1964-12-21       Impact factor: 56.272

2.  Central-core disease and malignant hyperpyrexia.

Authors:  M A Denborough; X Dennett; R M Anderson
Journal:  Br Med J       Date:  1973-02-03

3.  Malignant hyperthermia during anesthesia and surgery.

Authors:  J C Snow
Journal:  Arch Ophthalmol       Date:  1970-10

4.  Halothane-induced muscle contracture as a cause of hyperpyrexia.

Authors:  F R Ellis; D G Harriman; N P Keaney; K Kyei-Mensah; J H Tyrrell
Journal:  Br J Anaesth       Date:  1971-07       Impact factor: 9.166

5.  Metabolic error of muscle metabolism after recovery from malignant hyperthermia.

Authors:  W Kalow; B A Britt; M E Terreau; C Haist
Journal:  Lancet       Date:  1970-10-31       Impact factor: 79.321

6.  Unusual reaction to suxamethonium chloride.

Authors:  L W Hall; N Woolf; J W Bradley; D W Jolly
Journal:  Br Med J       Date:  1966-11-26

7.  Close linkage established between the HAL locus for halothane sensitivity and the PHI (phosphohexose isomerase) locus in pigs of the Danish Landrace breed.

Authors:  E Andresen; P Jensen
Journal:  Nord Vet Med       Date:  1977-11

8.  Kinetic studies of Ca2+ release from sarcoplasmic reticulum of normal and malignant hyperthermia susceptible pig muscles.

Authors:  D H Kim; F A Sreter; S T Ohnishi; J F Ryan; J Roberts; P D Allen; L G Meszaros; B Antoniu; N Ikemoto
Journal:  Biochim Biophys Acta       Date:  1984-09-05

9.  Abnormality in calcium release from skeletal sarcoplasmic reticulum of pigs susceptible to malignant hyperthermia.

Authors:  T E Nelson
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

10.  Dantrolene in human malignant hyperthermia.

Authors:  M E Kolb; M L Horne; R Martz
Journal:  Anesthesiology       Date:  1982-04       Impact factor: 7.892

View more
  13 in total

Review 1.  To fire the train: a second malignant-hyperthermia gene.

Authors:  K Hogan
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

2.  [Isoflurane-induced malignant hyperthermia during intensive-care treatment].

Authors:  B Wendlandt; S Turinsky; M Schmitz
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-01-15       Impact factor: 0.840

3.  The G1021A substitution in the RYR1 gene does not cosegregate with malignant hyperthermia susceptibility in a British pedigree.

Authors:  A M Adeokun; S P West; F R Ellis; P J Halsall; P M Hopkins; A M Foroughmand; D E Iles; R L Robinson; A D Stewart; J L Curran
Journal:  Am J Hum Genet       Date:  1997-04       Impact factor: 11.025

4.  Ryanodine receptor gene point mutation and malignant hyperthermia susceptibility.

Authors:  I Moroni; E F Gonano; G P Comi; V Tegazzin; A Prelle; A Bordoni; N Bresolin; G Scarlato
Journal:  J Neurol       Date:  1995-02       Impact factor: 4.849

5.  Mutation screening of the RYR1 gene and identification of two novel mutations in Italian malignant hyperthermia families.

Authors:  V Barone; O Massa; E Intravaia; A Bracco; A Di Martino; V Tegazzin; S Cozzolino; V Sorrentino
Journal:  J Med Genet       Date:  1999-02       Impact factor: 6.318

Review 6.  Channelopathies: ion channel defects linked to heritable clinical disorders.

Authors:  R Felix
Journal:  J Med Genet       Date:  2000-10       Impact factor: 6.318

Review 7.  Adverse effects of depolarising neuromuscular blocking agents. Incidence, prevention and management.

Authors:  W J Book; M Abel; J B Eisenkraft
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

8.  Diagnosis of malignant hyperthermia: a comparison of the in vitro contracture test with the molecular genetic diagnosis in a large pedigree.

Authors:  J M Healy; K A Quane; K E Keating; M Lehane; J J Heffron; T V McCarthy
Journal:  J Med Genet       Date:  1996-01       Impact factor: 6.318

Review 9.  [Malignant hyperthermia. The ugly].

Authors:  H Rüffert; M Wehner; C Deutrich; D Olthoff
Journal:  Anaesthesist       Date:  2007-09       Impact factor: 1.041

10.  Lack of prophylactic or therapeutic efficacy of 5-HT2A receptor antagonists in halothane-induced porcine malignant hyperthermia.

Authors:  W Löscher; C Gerdes; A Richter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-10       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.